Daclatasvir for the treatment of chronic hepatitis C.

  title={Daclatasvir for the treatment of chronic hepatitis C.},
  author={Elisabetta Degasperi and A Aghemo and Massimo Colombo},
  journal={Expert opinion on pharmacotherapy},
  volume={16 17},
INTRODUCTION Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangenotypic activity and low-moderate barrier to resistance suitable for IFN-free combination with other direct acting antivirals (DAAs). AREAS COVERED The present review summarizes… CONTINUE READING